• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Western Pharmacology Society >Pre-Transplant Mycophenolate Mofetil Pharmacokinetics in Mexican Children
【24h】

Pre-Transplant Mycophenolate Mofetil Pharmacokinetics in Mexican Children

机译：在墨西哥儿童预移植霉霉素Mofetil药代动力学

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mycophenolate mofetil is an immunosuppressive pro-drug frequently used to prevent renal graft rejection. It is hydrolyzed by esterases to obtain the active drug mycophenolic acid (MPA). There is high inter-patient variation in mycophenolic acid pharmacokinetics. Area under the concentration versus time curve (AUC) is used for therapeutic drug monitoring and recommended levels are 30-60 mug centre dot hr/L. The aim of this study was to determine mycophenolic acid pharmacokinetics in children awaiting renal allograft in order to predict mycophenolate mofetil dose requirements. Children with end-stage renal disease on the waiting list for renal allograft transplantation were invited to participate in the study. A nine-point pharmacokinetic profile was performed. All patients received a single dose (600 mg/m~2, subcutaneously) of mycophenolate mofetil at time zero. Mycophenolic acid was measured by HPLC. The AUC_(0-12h) was estimated by the trapezoidal rule. Ten children were included in the study. Mean age was 13.5 ± 3.5 years. The median AUC_(0-12h) was 20.3 mug centre dot hr/L, median C_(max) = 0.7 mug/mL. Two children (20%) had no detectable levels of mycophenolic acid after a single mycophenolate mofetil dose, other two patients had AUC > 60 mug centre dot hr/L One patient had abdominal pain 1 hr after the mycophenolate mofetil dose. Twenty percent of our patients had AUC_(0-12h) higher than the recommended value after a single mycophenolate mofetil dose, those patients should receive lower mycophenolate mofetil dose since the beginning of the transplant to avoid adverse events, and another 20% of patients had no detectable mycophenolic acid levels after a single mycophenolate mofetil dose. UGT1A9 gene polymorphisms remain to be studied in our patients, since they could explain the differences in bioavailability.
机译：霉酚酸酯是一种免疫抑制药物前体经常用于预防肾移植排斥。它是由酯酶水解，得到活性药物霉酚酸（MPA）。存在霉酚酸的药物动力学高的患者间变异。的浓度 - 时间曲线（AUC）下的面积被用于治疗药物监测和推荐的等级是30-60杯中心点hr / L的。这项研究的目的是确定以预测霉酚酸酯剂量要求儿童等待肾移植霉酚酸药代动力学。与肾移植移植等候名单上的终末期肾脏疾病的儿童被邀请参加了这项研究。进行了九个点药代动力学特性。所有患者在零时间接收的霉酚酸酯的单剂量（600毫克/米〜2，皮下）。霉酚酸通过HPLC测定。该AUC_（0-12h）由梯形法则估算。十个孩子被列入研究。平均年龄为13.5±3.5年。平均AUC_（0-12h）为20.3杯中心点小时/ L，中值C_（最大）= 0.7杯/毫升。两个孩子（20％）有霉酚酸的没有可检测水平的单霉酚酸酯剂量后，另外两个患者AUC> 60杯中心点hr / L的一名患者的霉酚酸酯剂量后腹痛1小时。我们的患者的百分之二十有AUC_（0-12h），比推荐值高后单霉酚酸酯剂量，这些患者应接受较低的霉酚酸酯剂量，因为移植的开头，以避免不良事件和患者的另外20％的人没有一个单一的霉后检测的霉酚酸吗乙酯水平剂量。 UGT1A9基因多态性留在我们的病人进行研究，因为它们可以解释生物利用度的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号